Skip to main content
Top
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Short report

Modulation of apoptosis by V protein mumps virus

Authors: Nora H Rosas-Murrieta, Gerardo Santos-López, Julio Reyes-Leyva, Francisca Sosa Jurado, Irma Herrera-Camacho

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Background

The Urabe AM9 vaccine strain of mumps virus contains two variants of V protein: VWT (of HN-A1081 viral population) and VGly (of HN-G1081). The V protein is a promoting factor of viral replication by blocking the IFN antiviral pathway.

Findings

We studied the relationship between V protein variants and IFN-α2b-induced apoptosis. V proteins decrease activation of the extrinsic IFN-α2b-induced apoptotic pathway monitored by the caspase 8 activity, being the effect greater with the VWT protein. Both V proteins decrease the activity of caspase 9 of the intrinsic apoptotic pathway. In a system without IFN, the VWT and VGly proteins expression promotes activation of caspases 3 and 7. However, when the cellular system was stimulated with IFN-α, this activity decreased partially. TUNEL assay shows that for treatment with IFN-α and ibuprofen of cervical adenocarcinoma cells there is nuclear DNA fragmentation but the V protein expression reduces this process.

Conclusions

The reduction in the levels of caspases and DNA fragmentation, suggesting that V protein, particularly VWT protein of Urabe AM9 vaccine strain, modulates apoptosis. In addition, the VWT protein shows a protective role for cell proliferation in the presence of antiproliferative signals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Randall RE, Goodbourn S: Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89: 1-47. 10.1099/vir.0.83391-0CrossRefPubMed Randall RE, Goodbourn S: Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89: 1-47. 10.1099/vir.0.83391-0CrossRefPubMed
2.
go back to reference Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC: Antiproliferative properties of Type I and Type II interferon. Pharmaceuticals 2010, 3: 994-1015. 10.3390/ph3040994PubMedCentralCrossRefPubMed Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC: Antiproliferative properties of Type I and Type II interferon. Pharmaceuticals 2010, 3: 994-1015. 10.3390/ph3040994PubMedCentralCrossRefPubMed
3.
go back to reference De Weerd NA, Samarajiwa SA, Hertzog PJ: Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007, 282: 20053-20057. 10.1074/jbc.R700006200CrossRefPubMed De Weerd NA, Samarajiwa SA, Hertzog PJ: Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007, 282: 20053-20057. 10.1074/jbc.R700006200CrossRefPubMed
4.
go back to reference Murray PJ: The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178: 2623-2629.CrossRefPubMed Murray PJ: The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178: 2623-2629.CrossRefPubMed
5.
go back to reference Gotoh B, Komatsu T, Takeuchi K, Yokoo J: Paramyxovirus accessory proteins as interferon antagonists. Microbiol Immunol 2001, 45: 787-800.CrossRefPubMed Gotoh B, Komatsu T, Takeuchi K, Yokoo J: Paramyxovirus accessory proteins as interferon antagonists. Microbiol Immunol 2001, 45: 787-800.CrossRefPubMed
6.
go back to reference Horvath CM: Weapons of STAT destruction. Interferon evasion by paramyxovirus V proteins. Eur J Biochem 2004, 271: 4621-4628. 10.1111/j.1432-1033.2004.04425.xCrossRefPubMed Horvath CM: Weapons of STAT destruction. Interferon evasion by paramyxovirus V proteins. Eur J Biochem 2004, 271: 4621-4628. 10.1111/j.1432-1033.2004.04425.xCrossRefPubMed
8.
go back to reference Moffitt KL, Martin SL, Walker B: Proteases implicated in apoptosis: old and new. J Pharm Pharmacol 2010, 62: 563-576.CrossRefPubMed Moffitt KL, Martin SL, Walker B: Proteases implicated in apoptosis: old and new. J Pharm Pharmacol 2010, 62: 563-576.CrossRefPubMed
9.
go back to reference Moffitt KL, Martin SL, Walker B: From sentencing to execution--the processes of apoptosis. J Pharm Pharmacol 2010, 62: 547-562.CrossRefPubMed Moffitt KL, Martin SL, Walker B: From sentencing to execution--the processes of apoptosis. J Pharm Pharmacol 2010, 62: 547-562.CrossRefPubMed
10.
go back to reference Tait SW, Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010, 11: 621-632. 10.1038/nrm2952CrossRefPubMed Tait SW, Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010, 11: 621-632. 10.1038/nrm2952CrossRefPubMed
11.
go back to reference Albert ML: Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004, 4: 223-231. 10.1038/nri11308CrossRefPubMed Albert ML: Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004, 4: 223-231. 10.1038/nri11308CrossRefPubMed
12.
go back to reference Benedict CA, Norris PS, Ware CF: To kill or be killed: viral evasion of apoptosis. Nat Immunol 2002, 3: 1013-1018. 10.1038/ni1102-1013CrossRefPubMed Benedict CA, Norris PS, Ware CF: To kill or be killed: viral evasion of apoptosis. Nat Immunol 2002, 3: 1013-1018. 10.1038/ni1102-1013CrossRefPubMed
13.
go back to reference Kubota T, Yokosawa N, Yokota S, Fujii N: C terminal Cys-rich region of mumps virus structural V protein correlates with block of interferon α and γ signal transduction pathway through decrease of STAT1-α. Biochem Biophys Res Commun 2001, 283: 255-259. 10.1006/bbrc.2001.4764CrossRefPubMed Kubota T, Yokosawa N, Yokota S, Fujii N: C terminal Cys-rich region of mumps virus structural V protein correlates with block of interferon α and γ signal transduction pathway through decrease of STAT1-α. Biochem Biophys Res Commun 2001, 283: 255-259. 10.1006/bbrc.2001.4764CrossRefPubMed
14.
go back to reference Nishio M, Tsurudome M, Ito M, Garcin D, Kolakofsky D, Ito Y: Identification of Paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J Virol 2005, 79: 8591-8601. 10.1128/JVI.79.13.8591-8601.2005PubMedCentralCrossRefPubMed Nishio M, Tsurudome M, Ito M, Garcin D, Kolakofsky D, Ito Y: Identification of Paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J Virol 2005, 79: 8591-8601. 10.1128/JVI.79.13.8591-8601.2005PubMedCentralCrossRefPubMed
15.
go back to reference Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grandér D: Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21: 1251-1262. 10.1038/sj.onc.1205179CrossRefPubMed Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grandér D: Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21: 1251-1262. 10.1038/sj.onc.1205179CrossRefPubMed
16.
go back to reference Santos-López G, Cruz C, Pazos N, Vallejo V, Reyes-Leyva J, Tapia-Ramírez J: Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect 2006, 8: 332-339. 10.1016/j.micinf.2005.06.031CrossRefPubMed Santos-López G, Cruz C, Pazos N, Vallejo V, Reyes-Leyva J, Tapia-Ramírez J: Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect 2006, 8: 332-339. 10.1016/j.micinf.2005.06.031CrossRefPubMed
17.
go back to reference Rosas-Murrieta N, Herrera-Camacho I, Vallejo-Ruíz V, Millán-Pérez-Peña L, Cruz C, Tapia-Ramírez J, Santos-López G, Reyes-Leyva J: Differential sensitivity to interferon influences the replication and transcription of Urabe AM9 mumps virus variants in nerve cells. Microbes Infect 2007, 9: 864-872. 10.1016/j.micinf.2007.03.005CrossRefPubMed Rosas-Murrieta N, Herrera-Camacho I, Vallejo-Ruíz V, Millán-Pérez-Peña L, Cruz C, Tapia-Ramírez J, Santos-López G, Reyes-Leyva J: Differential sensitivity to interferon influences the replication and transcription of Urabe AM9 mumps virus variants in nerve cells. Microbes Infect 2007, 9: 864-872. 10.1016/j.micinf.2007.03.005CrossRefPubMed
18.
go back to reference Rosas-Murrieta NH, Herrera-Camacho I, Palma-Ocampo H, Santos-López G, Reyes-Leyva J: Interaction of mumps virus V protein variants with STAT1-STAT2 heterodimer: experimental and theoretical studies. Virol J 2010, 7: 263. 10.1186/1743-422X-7-263PubMedCentralCrossRefPubMed Rosas-Murrieta NH, Herrera-Camacho I, Palma-Ocampo H, Santos-López G, Reyes-Leyva J: Interaction of mumps virus V protein variants with STAT1-STAT2 heterodimer: experimental and theoretical studies. Virol J 2010, 7: 263. 10.1186/1743-422X-7-263PubMedCentralCrossRefPubMed
19.
go back to reference Sun M, Rothermel TA, Shuman L, Aligo JA, Xu S, Lin Y, Lamb RA, He B: Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J Virol 2004, 78: 5068-5078. 10.1128/JVI.78.10.5068-5078.2004PubMedCentralCrossRefPubMed Sun M, Rothermel TA, Shuman L, Aligo JA, Xu S, Lin Y, Lamb RA, He B: Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J Virol 2004, 78: 5068-5078. 10.1128/JVI.78.10.5068-5078.2004PubMedCentralCrossRefPubMed
20.
go back to reference Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC: Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 2008, 82: 8965-8977. 10.1128/JVI.00853-08PubMedCentralCrossRefPubMed Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC: Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 2008, 82: 8965-8977. 10.1128/JVI.00853-08PubMedCentralCrossRefPubMed
21.
go back to reference Szewczyk A, Wojtczak L: Mitochondria as a pharmacological target. Pharmacol Rev 2002, 54: 101-127. 10.1124/pr.54.1.101CrossRefPubMed Szewczyk A, Wojtczak L: Mitochondria as a pharmacological target. Pharmacol Rev 2002, 54: 101-127. 10.1124/pr.54.1.101CrossRefPubMed
22.
go back to reference Wiegand M, Bossow S, Neubert WJ: Sendai virus trailer RNA simultaneously blocks two apoptosis-inducing mechanisms in a cell type-dependent manner. J Gen Virol 2005, 86: 2305-2314. 10.1099/vir.0.81022-0CrossRefPubMed Wiegand M, Bossow S, Neubert WJ: Sendai virus trailer RNA simultaneously blocks two apoptosis-inducing mechanisms in a cell type-dependent manner. J Gen Virol 2005, 86: 2305-2314. 10.1099/vir.0.81022-0CrossRefPubMed
23.
go back to reference Cruz CD, Palosaari H, Parisien JP, Devaux P, Cattaneo R, Ouchi T, Horvath CM: Measles virus V protein inhibits p53 family member p73. J Virol 2006, 80: 5644-5650. 10.1128/JVI.02400-05PubMedCentralCrossRefPubMed Cruz CD, Palosaari H, Parisien JP, Devaux P, Cattaneo R, Ouchi T, Horvath CM: Measles virus V protein inhibits p53 family member p73. J Virol 2006, 80: 5644-5650. 10.1128/JVI.02400-05PubMedCentralCrossRefPubMed
24.
go back to reference Thot AM, Devaux P, Cattaneo R, Samuel CE: Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol 2009, 83: 961-968. 10.1128/JVI.01669-08CrossRef Thot AM, Devaux P, Cattaneo R, Samuel CE: Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol 2009, 83: 961-968. 10.1128/JVI.01669-08CrossRef
25.
go back to reference Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC: The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001, 276: 28570-28577. 10.1074/jbc.M011685200CrossRefPubMed Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC: The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001, 276: 28570-28577. 10.1074/jbc.M011685200CrossRefPubMed
26.
go back to reference Battcock SM, Collier TW, Zu D, Hirasawa K: Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006, 80: 4422-4430. 10.1128/JVI.80.9.4422-4430.2006PubMedCentralCrossRefPubMed Battcock SM, Collier TW, Zu D, Hirasawa K: Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006, 80: 4422-4430. 10.1128/JVI.80.9.4422-4430.2006PubMedCentralCrossRefPubMed
Metadata
Title
Modulation of apoptosis by V protein mumps virus
Authors
Nora H Rosas-Murrieta
Gerardo Santos-López
Julio Reyes-Leyva
Francisca Sosa Jurado
Irma Herrera-Camacho
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-224

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine